The CEO of Arcus Biosciences talks TIGIT, adenosine, and HIF-2α at #ASCO24

blonca9
Jun 2, 2024
1 min read

Terry Rosen describes data presented at ASCO for TIGIT in upper GI cancers, adenosine in late state colorectal cancer, and non-ASCO data that will be coming up in the second half of the year for HIF-2α in renal.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

The CEO of Arcus Biosciences talks TIGIT, adenosine, and HIF-2α at #ASCO24

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight